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Objectives: To provide an updated document assessing the global, NSAID-specific, and time dependent
risk of gastrointestinal (GI) complications through meta-analyses of high quality studies.
Methods: An exhaustive systematic search was performed. Inclusion criteria were: RCT or controlled study,
duration of 5 days at least, inactive control, assessment of minor or major NSAID adverse effects,
publication range January 1985 to January 2003. The publications retrieved were assessed during a
specifically dedicated WHO meeting including leading experts in all related fields. Statistics were
performed conservatively. Meta-regression was performed by regressing NSAID adjusted estimates
against study duration categories.
Results: Among RCT data, indolic derivates provided a significantly higher risk of GI complications related
to NSAID use than for non-users: RR = 2.25 (1.00; 5.08) than did other compounds: naproxen: RR = 1.83
(1.25; 2.68); diclofenac: RR = 1.73 (1.21; 2.46); piroxicam: RR = 1.66 (1.14; 2.44); tenoxicam: RR = 1.43
(0.40; 5.14); meloxicam: RR = 1.24 (0.98; 1.56), and ibuprofen: RR = 1.19 (0.93; 1.54). Indometacin
users had a maximum relative risk for complication at 14 days. The other compounds presented a better
profile, with a maximum risk at 50 days. Significant additional risk factors included age, dose, and
underlying disease. The controlled cohort studies provided higher estimates: RR = 2.22 (1.7; 2.9).
Publication bias testing was significant, towards a selective publication of deleterious effects of NSAIDs
from small sized studies.
Conclusion: This meta-analysis characterised the ‘‘compound’’ and ‘‘time’’ aspects of the GI toxicity of
non-selective NSAIDs. The risk/benefit ratio of such compounds should thus be carefully and individually
evaluated at the start of long term treatment.
N
on-steroidal anti-inflammatory drugs (NSAIDs) are
widely used for the treatment of pain, fever, and
inflammation. The worldwide NSAID market for both
occasional and chronic users has been conservatively
estimated at over 60 million people, and some NSAIDs
(aspirin, naproxen, ibuprofen, etc) are among the most
popular over the counter drugs.1 2 Chronic NSAID treatment
effectively reduces the symptoms of many painful arthritic
syndromes, but induces adverse gastrointestinal (GI) com-
plications, ranging from abdominal discomfort to life
threatening GI ulceration, bleeding, and perforation.3 4
Indeed, through their non-specific inhibition of the two
cyclo-oxygenase isoenzymes, both aspirin and conventional
NSAIDs induce gastroduodenal damage,5 6 and are now
considered as a major cause of iatrogenic pathology.7 The
most common clinical manifestations of NSAID related GI
damage to tissue are a combination of gastroduodenal
erosions and ulcerations, often called NSAID induced
gastropathy,4 affecting 25–50% of chronic NSAID users.
NSAID induced gastropathy may limit long term NSAID
treatment and causes a significant financial burden to the
healthcare system.4 8 9
In the late 1980s and 1990s, drug related adverse reactions
observed with NSAIDs were assessed in epidemiological
studies, mostly cross sectional and case controlled. Their
results were pooled in several quantitative systematic
reviews10–12 aiming at clarifying the relationship between
NSAID use and GI complications. They concluded that
exposure to NSAIDs resulted in a threefold increase in the
risk of perforation, ulcers, or bleeding in comparison with the
risk for non-users. Additional risk factors were shown to be
an age greater than 60 years, a previous history of GI events,
concomitant corticosteroid and anticoagulant use, and the
presence of Helicobacter pylori. This latter risk factor has been
extensively explored in a recent meta-analysis.12 A synergism
was found between NSAIDs and H pylori infection in the risk
of peptic ulcers, despite the presence of still unknown sources
of heterogeneity in this relation. The odds ratio of developing
an ulcer when exposed to NSAIDs in the presence of H pylori
was evaluated as greater than 2.
However, despite the highest level of sophistication of
these quantitative systematic reviews, the studies included
might not be relaying the best level of evidence. As noted by
Hawkey,7 Bollini et al,9 and Gabriel et al,10 most of the meta-
analyses focused on cross sectional and retrospective trials,
but such designs have been shown to induce overestimated
results compared with randomised controlled trials (RCTs)
and/or controlled longitudinal cohort studies. The reasons are
that RCTs provide a more accurate way to control for
confounding factors and bias, and the odds ratios in this
Abbreviations: ANOVA, analysis of variance; GI, gastrointestinal;
NSAIDs, non-steroidal anti-inflammatory drugs; RCT, randomised
controlled trial; RR, relative risk
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setting are less conservative estimates than relative risk. A
meta-analysis of a high quality RCT is thus, according to the
Cochrane Collaboration, the best source of medical evidence.
Few attempts have been made to characterise the complex
time-effect relationship between NSAID intake and GI side
effects. The gaps in the available publications reflect the need
for further large epidemiological studies examining these
important questions. The need for additional research is
supported by the widespread use of conventional, non-
specific NSAIDs, despite the better GI safety profile of cyclo-
oxygenase-2 inhibitors or the combination of NSAIDs and
prostaglandins or proton pump inhibitors.13
Our goal was to provide an updated document accurately
assessing the risk of GI complications induced by the most
commonly used non-selective NSAIDs and to characterise the
relationship between the duration of exposure and the
relative risk of GI complications.
METHODS
An exhaustive search of all potentially appropriate publi-
cations was performed, following a predefined proto-
col. Electronic sources included Medline and Premedline,
Biosis Preview, Healthstar, Embase, Cochrane Library of
Randomised Controlled Trials, Current Contents, EBM
reviews, and the internet. Because all reports are not indexed
in these databases, we conducted a hand search of the
reference section. The strategy was derived from the sensitive
search strategy currently recommended by the Cochrane
Collaboration Musculoskeletal Group, and the results were
added to those provided by another validated method.14
We retrieved any RCT and controlled cohort study
assessing the relationship between exposure to NSAIDs
and adverse GI events. Seven NSAIDs were individually
investigated: indometacin, naproxen, diclofenac, piroxicam,
tenoxicam, meloxicam, and ibuprofen. Other compounds
Table 1 RCTs included in the analysis





19 Laerum et al Diclofenac 150 mg/day Recurrent renal colic 41 39 GI-minor
25 Wahlstro¨m et al Diclofenac 150 mg/day Heterotopic ossification after hip
arthroplasty
46 50 GI system disorders
37 Laurent et al Diclofenac 100 mg/day Proteinuria in glomerular diseases 14 12 GI-minor
43 Bassotti et al Diclofenac 150 mg/day Healthy volunteers 8 8 GI-minor
Indometacin 150 mg/day 8
27 Reis et al Diclofenac 150 mg/day Heterotopic ossification after hip
arthroplasty
90 90 GI-minor
34 Schnitzer et al Etodolac 800 mg/day Knee osteoarthritis 91 90 GI-minor
Nabumetone 1500 mg/day 89
40 Laine et al Etodolac 400 mg bid Gastrointestinal tolerability 18 16 GI-major
Naproxen 500 mg bid
22 Hoikka et al Flurbiprofen 200 mg/day Heterotopic ossification after hip
arthroplasty
34 34 GI-minor
30 Elmstedt et al Ibuprofen 1200 mg/day Heterotopic ossification after hip
arthroplasty
21 22 GI-minor




41 Persson et al Ibuprofen 1200 mg/day Heterotopic ossification after hip
arthroplasty
48 47 GI-minor
48 Doyle et al Ibuprofen 1200 mg/day Gastrointestinal tolerability 833 413 GI-minor
26 Schmidt et al Indometacin 75 mg/day Heterotopic ossification after hip
arthroplasty
102 99 GI system disorders
20 Kjaersgaard et al Indometacin 75 mg/day Heterotopic ossification after hip
arthroplasty
19 22 Any GI adverse
event
42 Scott et al Indometacin 25 mg/day Knee osteoarthritis 202 303 GI-minor
47 Eliakim et al Indometacin 150 mg/day Acute musculoskeletal disorders 65 513 GI-major
38 Berry et al Lornoxicam 12 mg/day Knee and hip osteoarthritis 44 42 GI-minor
21 Lemmel et al Meloxicam 15 mg/day Rheumatoid arthritis 162 147 GI system disorders
7.5 mg/day 159
46 Yocum et al Meloxicam 3.75-15 mg/day Osteoarthritis 464 157 Any GI adverse
event
Diclofenac 100 mg/day 153
33 Lipscomb et al Meloxicam 15 mg/day Gastrointestinal tolerability 15 15 GI-minor
Piroxicam 20 mg/day 14
35 Patoia et al Meloxicam 15 mg/day Gastrointestinal tolerability 13 13 GI-severe
Piroxicam 20 mg/day 13
36 Lund et al Meloxicam 15 mg/day Knee osteoarthritis 134 137 GI-minor
44 Dougados et al Meloxicam 15/22.5 mg/day Ankylosing spondylitis 120 121 GI-major
Piroxicam 20 mg/day 108
29 Simon et al Naproxen 500 mg/day Rheumatoid arthritis 138 101 GI ulcers
18 Gebuhr et al Naproxen 750 mg/day Heterotopic ossification after hip
arthroplasty
28 27 GI system disorders
49 Schiff et al Naproxen 1000 mg/day Knee osteoarthritis 116 116 GI-minor
31 Bono et al Oxaprozin 1200 mg/day Tendinitis and bursitis 43 43 GI-major
24 Prupas et al Tenidap 40-200 mg/day Rheumatoid arthritis 131 67 GI-minor
23 Gebuhr et al (2) Tenoxicam 40 mg/day Heterotopic ossification after hip
arthroplasty
35 35 GI system disorders




50 Szpalski et al Tenoxicam 20 mg/day Low back pain 37 36 GI-minor
39 Dougados et al (2) Ximoprofen 30 mg/day Ankylosing spondylitis 50 95 GI-minor
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(etodolac, nabumetone, flurbiprofen, lornoxicam, oxaprozin,
tenidap, ximoprofen) were considered as comparators
because data available for each compound were too sparse.
NSAIDs had to be compared with an inactive control (placebo
or non-exposed group). Drugs had to be orally given. In RCTs,
both groups had to be matched at inclusion for age, sex, and
history of GI events. Treatment duration had to be at least
5 days. The study purposes had to be: safety trials,
osteoarticular disorders, or prevention of heterotopic ossifica-
tion after major orthopaedic surgery. The studies had to be
published between January 1985 and January 2003. We
focused on English publications or reports
The publications retrieved were discussed for methodolo-
gical standards and inclusion criteria compatibility during a
specifically dedicated WHO meeting, which included leading
experts in the fields of rheumatology, gastroenterology,
endocrinology, public health, and quantitative epidemiology.
Divergences were solved by consensus. Quality scoring was
performed using the Jadad score15 for RCTs, whereas for
longitudinal studies we used a quality scoring algorithm
previously defined by our research group.16
Data extraction was performed by two independent authors
(FR, OB) to ensure accuracy in data encoding. Values from
intention to treat analyses were systematically used when
available; otherwise we considered per-protocol results. Hetero-
geneity was assessed before choosing the combination model
among the subgroups and in the summary assessment.
The meta-regression process was done in several steps.
Firstly, all RCTs were combined to obtain a summary
estimate. Thereafter, a subdivision was made according to
drug. Finally, the individual estimates were regressed against
the respective study durations. Sensitivity analyses were set
to explore the confounding effects of age (under versus over
60 years), study purpose (rheumatic diseases versus hetero-
topic ossification versus tolerability), dose and outcomes,
which were categorised in two classes. Minor GI events
included abdominal pain, nausea, constipation, diarrhoea,
and dyspepsia. Major events included any duodenal, gastric,
or intestinal ulcers, bleeding, perforation, hospitalisation, and
related death.
The a risks were set at 5% for association and 10% for
heterogeneity tests. The global and individual estimators
were surrounded by their 95% confidence intervals.
Publication bias was statistically explored by funnel plot
drawing (log of the relative risks against their precision,
symmetrical if no publication bias is present) and by
regressing standard normal deviates of the effects against
their precision (no difference from 0 on the y axis if no
publication bias is present).17 Statistical operations were
performed using registered copies of Comprehensive Meta-
analysis, version 1.0.25 (Biostat, Englewood NJ 07631, USA),
and Statistica 6.0 (Statsoft, France).
RESULTS
At the end of the bibliographic research, 1893 publications
were found. Among them, 527 were selected and reviewed
for minimal methodological quality requirements by two
authors (FR, OE). After excluding articles solely or pre-
dominantly dealing with the tertiary prevention of NSAID-
induced complications by prostaglandins (misoprostol) or
other agents, and studies providing insufficient data for
subsequent meta-analysis, 32 RCTs on NSAIDs18–31 33–50 and 13
major cohort studies on NSAIDs13 51–53 55–66 were included after
review by a specifically dedicated group of experts (see
tables 1 and 2). The duration of the included RCTs ranged
from 5 days to 1825 days. Among them, 15 studies investi-
gated the anti-inflammatory properties of the drugs in
rheumatic diseases, 10 focused on the prevention of hetero-
topic ossification after major orthopaedic surgery, 5 were GI
tolerability trials, 1 was on the improvement of recurrent
renal colic, and 1 was on the effect of diclofenac on
proteinuria in glomerular diseases. The total number of
patients was 5325 receiving active drugs and 3453 receiving
placebo in the RCT section. The trials were of good
quality according to the classification of Jadad, with a
median score of 70% (range 20–100). Most of the cohort
studies were matched for age and sex to enhance compar-
ability between groups, while almost all RCTs assessed
homogeneity between groups at inclusion for the major
confounding variables. The median daily doses were
1200 mg ibuprofen, 875 mg naproxen, 200 mg flur-
biprofen, 30 mg ximoprofen, 1200 mg oxaprozin, 150 mg
diclofenac, 800 mg etodolac, 75 mg indometacin, 120 mg
tenidap, 15 mg meloxicam, 20 mg tenoxicam and 20 mg
piroxicam.
Table 2 Longitudinal controlled cohort studies included in the analysis





59 Kurata et al Any N/A Gastrointestinal bleeding in
patients with dyspepsia
282 263 GI-major
56 Allison et al Any N/A Gastrointestinal ulcers 249 464 GI-major
51 Guess et al Any N/A Fatal upper GI haemorrhage or
perforation
134060 p/y 834051 p/y GI-major
60 McMahon et al Any N/A Upper GI haemorrhage and
perforation
25700 24550 GI-major
53 Carson et al Any N/A Upper tract bleeding 47136 44634 GI-major





57 MacDonald et al Any N/A Gastrointestinal toxicity 52293 73792 GI-major
GI-minor
52 Bloom et al Any N/A Gastrointestinal toxicity 33880 36200 GI-major
Cost GI-minor
61 Smalley et al Any N/A Incidence of hospitalisations for
peptic ulcer disease in elderly
people
1000 p/y 1000 p/y GI-major
58 Fries et al Any N/A Serious GI events 1694 1053 GI-major
62 Garcia Rodriguez et al Any N/A Hospitalisation for upper GI
bleeding
700000 GI-major
63 Beard et al Any N/A Hospitalisation for gastro-
oesophageal bleeding
6095000 p/d 38006000 GI-major
13 Mamdani et al Any N/A Upper GI tract bleeding 5291 100000 GI-major
p/d, person-day; p/y, person-year.
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Summary of effects
Among the seven primary NSAIDs investigated, the risk of GI
complications due to NSAIDs compared with the risk for
non-users was estimated at 1.54 (1.4; 1.7) at a median
exposure time of 28 days in the RCTs (fig 1). Cohort studies
provided a global relative risk of 2.2 (1.7; 2.9) and a median
duration of 365 days (fig 4).
Subgroup analyses
Among the RCT of the seven mainly investigated NSAIDs
(fig 1), indometacin provided a significantly higher risk
for GI complication: RR=2.25 (1.01; 5.07), followed by
naproxen: RR=1.83 (1.25; 2.68), diclofenac: RR=1.73 (1.21;
2.46), piroxicam: RR=1.66 (1.14; 2.44), tenoxicam:
RR=1.43 (0.40; 5.14), meloxicam: RR=1.24 (0.98; 1.56),
and ibuprofen: RR=1.19 (0.93; 1.54). The other NSAIDs
(etodolac, flurbiprofen, lornoxicam, nabumetone, oxaprozin,
tenidap, and ximoprofen) provided RR=1.64 (1.2; 2.26). The
proportion of minor and major GI events studied among
those trials was significantly homogeneous among the seven
primary NSAIDs investigated (Pearson’s x2, p.0.05). The
meta-regression for non-indometacin NSAIDs, grouped
together, provided a duration of treatment of 84 days as
threshold for a significant risk of GI effects (fig 2). At seven
Figure 1 Relative risk of GI complications depending on NSAID (RCT).
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days of exposure, indometacin at 150 mg daily significantly
increased the risk (fig 3) Both categories of compounds
displayed a non-linear response of reported risks against
study durations.
Sensitivity analyses
The mean age of patients included in these studies had no
significant influence on the reported relative risks: RR=1.67
(1.02; 2.7) for studies in patients over 60 and RR=1.82 (1.15;
2.87) for patients under 60 (analysis of variance (ANOVA),
p=0.84). The relative risk for GI complications was
significantly affected by increasing the daily dose of
indometacin (Kendall’s t test, p,0.05), while this covariant
remained non-significant for the other compounds. For non-
indometacin compounds, we found a significant difference in
risk between patients enrolled in tolerability trials: RR=1.28
(1.04; 1.59) and patients with osteoarthritis/rheumatoid
arthritis or taking NSAIDs after hip arthroplasty: RR=1.54
(1.38; 1.7). The risk for minor events was RR=1.35 (1.14;
1.59) and RR=1.74 (1.26; 2.41) (ANOVA21, p=0.49) for
major events. For indometacin trials, insufficient data were
present to assess the role of the study purpose. The relative
risks for minor and major events were RR=1.45 (1.18; 1.78)
and RR=2.97 (1.03; 8.5) (ANOVA21, p,0.01).
The cohort studies assessing various NSAIDs (fig 4)
reported slightly higher estimates: RR=2.17 (1.76; 2.67)
for 1 year and below, and RR=1.45 (1.19; 1.75) for studies
between 2 and 3 years. Four studies assessed the GI adverse
effects in cohorts during more than 3 years, and reported
RR=2.87 (1.4; 5.9). It was noted that, in this analysis, both
intra- and intervariability were high (Cochrane’s Q, p,0.01),
reflecting the lower level of selection of patients and control
for bias.
Funnel plots appeared to be asymmetric for the RCT on
NSAIDs (fig 5). Indeed more small sized studies reporting a
Figure 2 Meta-regression of relative risk against study duration (non-
indometacin compounds).
Figure 3 Meta-regression of relative risk against study duration
(indometacin).
Figure 4 Relative risk of GI complications provided by longitudinal controlled cohort studies. PUB, perforation, ulcers, or bleeding.
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marked deleterious effect were retrieved compared with
studies reporting no or a less marked adverse effect
(ratio=1.29). The statistical method confirmed this pre-
liminary inspection (p,0.05). This means that, in reality, a
higher proportion of trials showing lower risks for adverse
effects due to NSAIDs have been performed compared with
the fraction of published papers showing marked effects.
DISCUSSION
Throughout the history of NSAIDs we have seen an overall
increase in their potency and this has been accompanied, on
the whole, by attempts and refinements to improve their
tolerability.64 Despite this trend, however, the classic GI side
effects of NSAIDs are just as much a feature of treatment
with contemporary drugs as they were with aspirin itself, and
in this context it is amazing that aspirin was thought initially
to be a better tolerated drug in the stomach than the salicylic
acid from which it was derived. Nevertheless, currently,
NSAIDs are the best recognised cause of iatrogenic pathology.
They have been estimated to cause as many as 16 500 deaths
a year in the America.65 These drugs exhibit a wide range of
actions resulting from local and systemic mechanisms, or a
combination of both, which contribute to their overall
toxicity.66
In this quantitative review of English publications, which
focused on RCTs and cohort studies, we found deleterious
effects of NSAIDs as soon as 1 week after the start of
treatment with indometacin. Nevertheless, the magnitude of
the risk shown by our results seems to be consistently less
alarming than that previously published.10 67–73 This can be
partially explained by the conservative approach we used. For
instance, relative risk was used to assess causality instead of
an odds ratio. Using odds ratios can lead to overestimated
global estimates compared with relative risk, in the analysis
of prospective data.74 Another possible explanation relates to
the fact that we restricted our survey to articles published
after 1985. Prior studies might differ because they no longer
reflect current practice, and may be of smaller size. We
decided to include RCTs and cohort studies. The rationale for
this approach was that while we expect the risk estimate to
be less biased when derived from RCTs, the populations being
studied in such trials are usually highly selected groups and,
therefore, are not always fully representative of the patients
seen in clinical practice. On the other hand, the analysis
performed using non-RCT longitudinal trials provide esti-
mates that may be more representative of daily clinical
practice, despite a lack of precision about the NSAIDs used.
Furthermore, there is evidence that case-control studies yield
exaggerated estimates of effect compared with cohort
studies.75 76
In this meta-analysis, we found that indometacin induces
a significant risk of GI side effects after less than 1 week of
treatment, whereas other non-specific NSAIDs ‘‘required’’
more than 1 month to induce deleterious effects. Ibuprofen
was the safest drug, while naproxen and diclofenac exhibited
a higher risk than the investigated oxicams (piroxicam,
tenoxicam, and meloxicam), which is consistent with
previous findings.5
Conflicting results have been reported on the relationship
between the risk of GI events and the duration of exposure to
NSAIDs. A number of epidemiological studies have suggested
that the risk of GI complications is higher at the onset of long
term NSAID treatment.13 77 The findings of this meta-analysis
support this claim. The use of meta-regression showed that
the maximum risk appeared at 14 days for indometacin, and
at 50 days for other NSAIDs. However, prospective experi-
mental studies suggest a steady increase in the rate of GI
complications over time.78 These differences may be
explained by the fact that patients who have not been taking
NSAIDs appear to have an increased risk of developing ulcers
and clinical events after starting NSAID treatment compared
with those who have already been taking NSAIDs. This is
related to a selection process of NSAID tolerant patients.
Our data come from studies with various purposes—for
example, safety trials versus efficacy trials in patients
requiring NSAIDs. Most of the RCTs focused on patients
with osteoarticular diseases, mostly osteoarthritis and rheu-
matoid arthritis (75%). We found a significant difference in
risk between patients without disease (RR=1.3, NS) and
patients with osteoarthritis or rheumatoid arthritis (RR=1.7,
p=0.035). These findings support the claim that the under-
lying disease requiring NSAID treatment may have a role in
the development of GI damage. More studies are needed to
assess this point clearly.
This meta-analysis showed a higher risk for major than for
minor GI side effects. The explanation is that most of the
studies in the first subgroup assessed preclinical erosion of
the gastric mucosa as an end point. It has been known for
more than 10 years that ulcers defined as breaches in the
mucosa may develop within 1 week of regular NSAID use.79
Furthermore, the mean age of patients in whom perforation,
ulcers, or bleeding were assessed was significantly higher
than that of patients in whom minor discomforts were
reported (Mann-Whitney U, p=0.04), and they were
exposed for a non-significantly longer period to NSAIDs
(Mann-Whitney U, p=0.29).
Selective inhibitors of the isoenzyme II of cyclo-oxygenase
are now marketed in most North American and European
countries for the symptomatic management of osteoarthritis
and rheumatoid arthritis. These compounds have, repeatedly,
demonstrated that they induce a lower incidence of GI side
effects than conventional NSAIDs.80 Other studies have also
reported a decrease in the GI toxicity of NSAIDs when
combined with prostaglandin analogues (misoprostol).81 82
However, coxibs and prostaglandin analogues are signifi-
cantly more expensive than conventional NSAIDs and are not
yet widely available to every patient requesting treatment
with NSAIDs, which means that the use of non-selective
NSAIDs as first line treatment is high and is increasing.83 84
CONCLUSION
The appearance of GI side effects induced by NSAIDs is time
dependent but depends less on the drug used. Indometacin at
150 mg daily can exhibit significant deleterious effects as
soon as 7 days after initiation of treatment, whereas other
NSAIDs, at their recommended therapeutic dose, usually
Figure 5 Funnel plot.
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induce GI effects after 2–3 months. Depending on the study
design, exposure time, compound, and underlying disease,
the relative risks of GI adverse reactions compared with
untreated controls vary from 1.2 to 5.6. This meta-analysis
demonstrates that NSAIDs should be given cautiously to
patients requiring long term management of chronic disease.
The risk/benefits ratio of such compounds should be carefully
and individually evaluated.
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